L-Glutamic Acid Hcl
L-Histidine Hcl
L-Lysine Acetate
L-Lysine Hcl
L-Ornithine Hcl
L-Pyroglutamic Acid
L-Homoarginine Hcl
DL-Arginine HCL
DL-Aspartic Acid
DL-Carnitine HCL
DL-Glutamic Acid
DL-Lysine Hcl
DL-Pyroglutamic Acid
D-Glucosamine Hcl
D-Glutamic Acid
D-Pyroglutamic Acid
D-Aspartic Acid
D-Arginine Hcl
D-Histidine Hcl
D-Ornitine Hcl


(CAS: 74-79-3)

Recommend Site

Synonyms: (S)-2-amino-5-guanidinopentanoic acid, S(+)-2-amino-5-[(aminoiminomethyl)amino]pentanoic acid, 2-amino-5-guanidinovaleric acid2

Molecular Formula: C6H14N4O2
Molecular Weight: 174.2
CAS: 74-79-3
pI: 10.76
pKa: 1.82 (COOH), 8.99 (-NH2), 12.48 (guanido group)
Specific Rotation: 26.9 (16.5 mg/ml, 6.0 N HCl,20 C)

Appearance: White powder
Solubility: Clear colorless solution @ 50mg/ml in water
IR spectrum: Consistent with structure
Carbon: 40.5% to 42.1%
Nitrogen: 31.5% to 33.0%
Purity(by Thin Layer Chromatography): Not less than 98%
Shelf life:3 years

L-Arginine is one of the three amino acids with basic side chains, and is very hydrophilic in character. It contains a guanidino group in the side chain, and this moiety is protonated at physiological pH. Arginine is biosynthesized in the kidneys from citrulline, whose precursor is glutamate via the formation of ornithine.In amino acid degradation in vivo, arginine is hydrolyzed to urea and ornithine by arginase. Arginine can be metabolized to glutamate, which in turn is converted to -ketoglutarate for entry into the citric acid cycle. L-Arginine is used in cell culture as a component of MEM amino acids solution. Cells utilize L-arginine as a precursor for the production of nitric oxide (NO), which is an activator of guanylyl cyclase and leads to the production of the second messenger cGMP. The production of NO from cultured porcine aortic endothelial cells has been demonstrated. Virulence gene expression in a tRNA modificationdeficient mutant of Shigella flexneri has been modulated by the addition of
L-arginine. A study of the effects of L-arginine on cultured human osteoblasts has been reported, with relation to bone metabolism and growth. An investigation of varying the environment for growth of Escherichia coli between growth in the presence of excess nitrogen (ammonia) to nitrogen starvation, where L-arginine is used as an alternate nitrogen source, has been reported.
Preparation Instructions: This product is soluble in water (50 mg/ml), yielding a clear, colorless solution.
Storage/Stability: Solutions of L-arginine may be autoclaved. Aqueous solutions of this product are strongly alkaline and tend to absorb carbon dioxide from the atmosphere on standing.

L-arginine is a protein amino acid present in the proteins of all life forms. It is classified as a semi-essential or conditionally essential amino acid. This means that under normal circumstances the body can synthesize sufficient L-arginine to meet physiological demands. There are, however, conditions where the body cannot. L-arginine is essential for young children and for those with certain rare genetic disorders in which synthesis of the amino acid is impaired. Some stress conditions that put an increased demand on the body for the synthesis of L-arginine include trauma (including surgical trauma), sepsis and burns. Under these conditions, L-arginine becomes essential, and it is then very important to ensure adequate dietary intake of the amino acid to meet the increased physiological demands created by these situations.

L-arginine, even when it is not an essential amino acid as defined above, is a vital one. In addition to participating in protein synthesis, it plays a number of other roles in the body. These include the detoxification of ammonia formed during the nitrogen catabolism of amino acids via the formation of urea. In addition, L-arginine is a precursor in the formation of nitric oxide, creatine, polyamines, L-glutamate, L-proline, agmatin (a possible neurotransmitter in the brain) and the arginine-containing tetrapeptide tuftsin, believed to be an immunomodulator. L-arginine is a glycogenic amino acid; it can be converted to D-glucose and glycogen if needed by the body or it can be catabolized to produce biological energy.

L-arginine, when administered in high doses, stimulates pituitary release of growth hormone and prolactin and pancreatic release of glucagon and insulin. Intravenous L-arginine may be used as an aid in the evaluation of problems with growth and stature that may be due to growth hormone deficiency. Intravenous arginine hydrochloride may be used as a fourth-line agent in the treatment of severe metabolic alkalosis. L-arginine is also used as an immunonutrient in enteral and parenteral nutrition to help improve the immune status in those suffering from sepsis, burns and trauma.

L-arginine is predominately synthesized in the kidney. It is a key intermediate in the Krebs-Henseleit urea cycle. L-ornithine and L-citrulline are precursors in the synthesis of L-arginine, and L-arginine is converted to urea and L-ornithine via the enzyme arginase. The portion of L-arginine that is not converted to urea enters the circulation, and is distributed to the various tissues and metabolized as discussed above. A much smaller amount of L-arginine is produced in the liver.

The typical dietary intake of L-arginine is 3.5 to 5 grams daily. Most dietary L-arginine comes from plant and animal proteins. Small amounts of free L-arginine are found in vegetable juices and fermented foods, such as miso and yogurt. Soy protein and other plant proteins are richer in L-arginine than are animal proteins, which are richer in lysine. It is thought that the possible hypocholesterolemic effect of soy protein is due, at least in part, to the higher L-arginine content in this protein.

L-arginine is a basic amino acid with the molecular formula C6H14N4O2 and with a molecular weight of 174.20 daltons. It has 3 pKs: pK1=2.18, pK2=9.09 and pK3=13.2. Therefore, it carries a positive charge at physiological pH. The stereoisomer of L-arginine, D-arginine, does not have any biological activity, as far as we know. L-arginine is also known as 2-amino-5-guanidinovaleric acid and (S)-2-amino-5-[(aminoiminomethyl)amino] pentaenoic acid. Its one-letter abbreviation is R. It is also abbreviated as Arg. The terms L-arginine and arginine are frequently used interchangeably. The structural formula of L-arginine is as follows:

Supplemental L-arginine may have anti-atherogenic, antioxidant and immunomodulatory actions. It may also have wound-repair activity.

Many of supplemental L-arginine's activities, including its possible anti-atherogenic actions, may be accounted for by its role as the precursor to nitric oxide or NO. NO is produced by all tissues of the body and plays very important roles in the cardiovascular system, immune system and nervous system. NO is formed from L-arginine via the enzyme nitric oxide synthase or synthetase (NOS), and the effects of NO are mainly mediated by 3,'5' -cyclic guanylate or cyclic GMP. NO activates the enzyme guanylate cyclase, which catalyzes the synthesis of cyclic GMP from guanosine triphosphate or GTP. Cyclic GMP is converted to guanylic acid via the enzyme cyclic GMP phosphodiesterase.

NOS is a heme-containing enzyme with some sequences similar to cytochrome P-450 reductase. Several isoforms of NOS exist, two of which are constitutive and one of which is inducible by immunological stimuli. The constitutive NOS found in the vascular endothelium is designated eNOS and that present in the brain, spinal cord and peripheral nervous system is designated nNOS. The form of NOS induced by immunological or inflammatory stimuli is known as iNOS. iNOS may be expressed constitutively in select tissues such as lung epithelium.

All the nitric oxide synthases use NADPH (reduced nicotinamide adenine dinucleotide phosphate) and oxygen (O2) as cosubstrates, as well as the cofactors FAD (flavin adenine dinucleotide), FMN (flavin mononucleotide), tetrahydrobiopterin and heme. Interestingly, ascorbic acid appears to enhance NOS activity by increasing intracellular tetrahydrobiopterin. eNOS and nNOS synthesize NO in response to an increased concentration of calcium ions or in some cases in response to calcium-independent stimuli, such as shear stress.

In vitro studies of NOS indicate that the Km of the enzyme for L-arginine is in the micromolar range. The concentration of L-arginine in endothelial cells, as well as in other cells, and in plasma is in the millimolar range. What this means is that, under physiological conditions, NOS is saturated with its L-arginine substrate. In other words, L-arginine would not be expected to be rate-limiting for the enzyme, and it would not appear that supraphysiological levels of L-arginine^which could occur with oral supplementation of the amino acid^would make any difference with regard to NO production. The reaction would appear to have reached its maximum level. However, in vivo studies have demonstrated that, under certain conditions, e.g. hypercholesterolemia, supplemental L-arginine could enhance endothelial-dependent vasodilation and NO production.

The discordance between the in vivo results^increased NO production under certain conditions^and the in vitro enzyme studies described above is known as the "arginine paradox." There are a few explanations for the "arginine paradox." NOS may be inhibited by asymmetric dimethylarginine or ADMA, which is known to be elevated in hypercholesterolemia and which increases mononuclear cell (monocyte and T-lymphocyte) adhesiveness in hypercholesterolemics. ADMA is formed by post-translational methylation of L-arginine residues in proteins and is released from the proteins following their hydrolysis. The "arginine paradox" may be explained in part by increasing levels of L-arginine overcoming the inhibition of NOS by ADMA. In addition to hypercholesterolemia, elevated levels of ADMA are associated with hypertension, diabetes, preeclampsia, smoking and aging. Elevation of ADMA may be due to altered metabolism of this substance by dimethylarginine dimethylaminohydrolase or DDAH. DDAH is the major enzyme involved in ADMA catabolism. Decreased levels of DDAH have been found in diabetic and hypercholesterolemic animal models.

Other explanations of the "arginine paradox" include the presence of other inhibitors of NOS yet to be discovered, impaired transport of L-arginine into or within endothelial cells and impaired regeneration of L-arginine from L-citrulline. There is another interesting possibility. A non-enzymatic pathway by which NO may be produced has recently been described. Endothelial dysfunction is associated with increased oxidative stress resulting in increased formation of such reactive oxygen species as hydrogen peroxide and superoxide anions. Further, during conditions of oxidative stress, enzymatic synthesis of NO may decrease, and NO reacts with superoxide anions to form the reactive nitrogen species peroxynitrite. Under these conditions, L-arginine can essentially scavenge hydrogen peroxide and superoxide to form NO non-enzymatically. Interestingly, in this non-enzymatic reaction, L-arginine, as well as the non-biological D-arginine, can both form NO.

NO formed from supplemental L-arginine can play a major role in the possible anti-atherogenic activity of L-arginine. NO inhibits mononuclear cell adhesion, platelet aggregation, proliferation of vascular smooth muscle, production of some reactive oxygen species, such as superoxide anions, and promotion of endothelium-dependent dilation. Leukocyte adhesion, platelet aggregation, smooth muscle proliferation, endothelial dysfunction and oxidative stress are all part of the process of atherogenesis. L-arginine may also have anti-atherogenic activity independent of its role in the enzymatic formation of NO.

L-arginine may itself have antioxidant activity. L-arginine has been found to inhibit the oxidation of low-density lipoproteins (LDL) to oxidized LDL (oxLDL). The oxidation of LDL to oxLDL is believed to be a pivotal early step in atherogenesis. L-arginine may also scavenge superoxide anions and hydrogen peroxide (see above), as well as inhibit lipid peroxidation.

L-arginine has been shown to have immunomodulatory activity. For example, in human breast cancer, supplementation with this amino acid has been reported to increase the quantity and cytotoxic activity of natural killer (NK) cells and lymphokine-activated-killer (LAK) cells. L-arginine is considered an immunonutrient and is added to enteral and parenteral feedings for burn, sepsis and trauma patients. The mechanism of L-arginine's possible immunomodulating activity is not entirely clear. It may, at least in part, be again due to L-arginine's role in the production of NO. Production of NO, with consequent decrease of the cyclic AMP/cyclic GMP ratio in NK cells, would favor the production of interleukin-1, which is known to activate NK cells and may directly enhance NK cell cytotoxicity. L-arginine is also a precursor in the synthesis of the tetrapeptide tuftsin, which itself appears to have immunomodulatory activity. Tuftsin's activity appears to depend on two of the four amino acids present in its structure, L-arginine and L-proline. L-arginine also participates in the synthesis of L-proline.

L-arginine's possible activity in wound repair may be due to its precursor role in the formation of L-ornithine and, ultimately, L-proline. L-proline is a key element in collagen biosynthesis.

Following ingestion, L-arginine is absorbed from the lumen of the small intestine into the enterocytes. Absorption is efficient and occurs by an active transport mechanism. Some metabolism of L-arginine takes place in the enterocytes. L-arginine not metabolized in the enterocytes enters the portal circulation from whence it is transported to the liver, where again some portion of the amino acid is metabolized. L-arginine not metabolized in the liver enters the systemic circulation, where it is distributed to the various tissues of the body. L-arginine participates in various metabolic activities, including the production of proteins, D-glucose, glycogen, L-ornithine, urea, nitric oxide, L-glutamate, creatine, polyamines, L-proline, agmatin and tuftsin. L-arginine is eliminated by glomerular filtration and is almost completely reabsorbed by the renal tubules. L-arginine produces peak plasma levels approximately one to two hours after oral administration.

L-arginine shows promise in the treatment and prevention of cardiovascular disease (including atherosclerosis, hypertension, hyperlipidemia and angina pectoris), in the treatment of some forms of male infertility and some kidney disorders and it is helpful in accelerating wound healing in some circumstances. It has demonstrated some positive immune-modulating and anticancer effects. There is preliminary evidence that it could be helpful in some men with erectile dysfunction and in some others with migraine, liver disease and primary ciliary dyskinesia. There is conflicting but mostly negative evidence related to claims that it can improve exercise performance and promote lean muscle mass.

Numerous in vitro experiments have shown that L-arginine has effects on endothelial cells that could be expected to inhibit cardiovascular disease. Inferences have been drawn from these studies suggesting that L-arginine, through its nitric oxide activity, especially in the endothelial cells of the blood vessels, inhibits vasoconstriction, thrombolytic activity, cell proliferation, inflammation and other activities that promote cardiovascular disease.

Some of the promise of these in vitro studies has been realized in animal and clinical studies. In hypercholesterolemic animal models, L-arginine helps normalize lipids and vasodilatory response, inhibits platelet aggregation and formation of intimal lesions. Further, it has been seen in some of these animal studies to cause pre-existing lesions to regress.

Similarly, L-arginine has had significant positive effects in hypercholesterolemic and hypertensive humans. It has also been helpful in those with angina pectoris. In a recent long-term study, supplemental L-arginine, given for six months, resulted in significant improvement in coronary small-vessel endothelial function associated with a decrease in plasma endothelin concentrations.

In a double-blind, placebo-controlled study of 22 subjects with stable angina, supplemental L-arginine (1 gram twice daily) significantly improved exercise capacity. L-arginine supplementation resulted in a 70% reduction in angina attacks in another study.

In other studies, L-arginine was credited with significantly reducing lipid peroxidation in patients with diabetes mellitus. Conflicting results were produced by two studies related to L-arginine's effects on vasomotor response in smokers. In one of these studies, L-arginine significantly reversed abnormal myocardial blood flow response to a cold pressor test; in the other small study, no significant positive effect was seen.

The treatment of oligospermia with L-arginine was first reported many years ago. In one of these early studies, 178 men with oligospermia were given 4 grams of L-arginine daily. Severe oligospermia was diagnosed in 93 of these subjects. Treatment ceased in subjects who showed no improvement after two months. A 100% increase in sperm count was achieved in 42 cases, resulting in 15 pregnancies. There was marked increase in sperm number and motility in an additional 69 patients, resulting in another 13 pregnancies.

Subsequent studies have shown that L-arginine improves sperm count and motility. A recent small study credited L-arginine with producing pregnancies, but larger clinical trials are needed to confirm the efficacy seen in the early work.

L-arginine is of benefit in some kidney diseases and shows some promise in interstitial cystitis. It helps improve kidney function in some diabetic animal models and prevents chronic renal failure in others. A recent study indicated that L-arginine facilitates renal vasodilatation and natriuresis in renal transplant patients. There was also the suggestion in this study that L-arginine counteracts the antinatriuretic effect of cyclosporin.

Several studies have found that L-arginine benefits some with interstitial cystitis. Other studies, however, have not reported benefit. It appears that L-arginine can decrease pain and urgency in some subsets of interstial cystitis patients, but more research is needed to confirm this.

L-arginine has long been used following trauma and during sepsis. Studies have shown that L-arginine improves nitrogen balance and thus reduces protein catabolism. Animal studies have shown that L-arginine can be of significant benefit after severe burn injury, increasing survival, improving cardiac function and preventing bacterial translocation. Intravenous L-arginine has been helpful in some human traumas, helping to speed healing while inhibiting post-injury wasting and weight loss.

L-arginine shows many effects on immune function both in vitro and in vivo. In various animal studies, L-arginine has, reportedly, improved host immunity in a variety of conditions through its effects on the thymus and T-lymphocytes. It has also been reported to reduce the incidence of chemically induced tumors and to reduce the size of pre-existing tumors. It has significantly inhibited metastatic spread of some cancers in animal work.

In human work, oral L-arginine has increased the responsiveness of some immune components and has decreased the number and percent of T suppressor/cytotoxic cells (CD8) in healthy human volunteers. In a clinical trial involving patients undergoing abdominal surgery, intravenous L-arginine diminished postoperative reduction in the mitogenic responses of peripheral blood lymphocytes to ConA and PHA. Enhancement of these same responses was reported in a study in which L-arginine was given to HIV patients. L-arginine supplementation in this study, did not, however, alter T-lymphocyte subsets or ratios.

In a more recent study of L-arginine's effects in HIV-infected subjects, supplementation for six months (7.4 grams daily) failed to produce any improvement in immunological parameters measured, but body weight increased in L-arginine-supplemented subjects.

In healthy human volunteers, administering 30 grams of L-arginine daily for three days resulted in enhanced natural-killer (NK) and lymphokine-activated-killer (LAK) cell activity. A mean rise of 91% in NK cell activity and a mean rise of 58% in LAK cell activity were observed. The researchers concluded: "The substantial enhancement of human NK and LAK cell activity by large doses of L-arginine could be useful in many immunosuppressed states, including malignant disease, AIDS and HIV infection, in which depressed NK cell activity is an important component of the disease process."

Supplementation with L-arginine has significantly increased the quantity and cytotoxic activity of NK cells and lymphokine-activated cells in patients with breast cancer in one study. Research is ongoing.

There is recent, preliminary evidence that oral L-arginine can help some men with erectile dysfunction. In a double-blind, placebo-controlled study, 50 men with this disorder were randomized to receive 5 grams of L-arginine daily or placebo for six weeks. Nine of 29 L-arginine-supplemented subjects and two of 17 controls reported significant subjective improvement in erectile function. All nine of the L-arginine responders had low urinary levels of stable metabolites of nitric oxide at baseline. These levels doubled by the end of the study. More research is needed.

In another recent study, L-arginine was found to be helpful in subjects suffering from primary ciliary dyskinesia, a genetic disorder characterized by impaired cilia motility and abnormally low levels of nasal nitric oxide. L-arginine, in combination with ibuprofen, also proved helpful in significantly reducing migraine pain intensity compared with placebo in another recent, preliminary, multi-center study of 40 migraine patients.

Research related to L-arginine's claimed hepatoprotective effects is dated. The data, however, looked promising and deserve follow-up.

Claims that L-arginine enhances exercise performance and promotes development of lean body mass while burning fat in healthy individuals are poorly supported. Weight gain was decreased in obese mice fed L-arginine, but there are no human data to support anti-obesity claims for L-arginine.

There are hypothetical reasons to believe that L-arginine, popular with some body builders, might have ergogenic/anabolic effects but, so far, these effects have not been demonstrated. High dose oral L-arginine has, however, been shown to induce release of growth hormone and prolactin but, again, no studies have been conducted to see whether this could have any meaningful ergogenic or anabolic effect.

Supplemental L-arginine is contraindicated in those with the rare genetic disorder argininemia. It is also contraindicated in those hypersensitive to any component of an arginine-containing preparation.

Because of absence of long-term safety studies, and because of the possibility of growth hormone stimulation, pregnant women and nursing mothers should avoid L-arginine supplementation.

Those with renal or hepatic failure should exercise caution in the use of supplemental L-arginine.

Proteins of the herpes simplex virus are rich in L-arginine, and there are a few reports (mainly anecdotal) of those taking supplemental L-arginine who have had recurrences of oral herpes lesions. Although it is unlikely that those with a history of herpes simplex virus infection will have recurrences if they use L-arginine supplements, they should nevertheless be aware of this possibility.